Founded by Steve Case in 2005, Revolution partners with passionate entrepreneurs upending traditional industries with innovative products and services, leveraging its areas of specialized expertise to create significant value. Through its family of funds that include The Rise of the Rest Seed Funds, Revolution Ventures, and Revolution Growth, Revolution partners with entrepreneurs at every stage of the entrepreneurial lifecycle. Revolution focuses on venture communities in high-potential geographies and believes that while talent is well distributed, the opportunity is not. The firm’s vision that great companies can start and scale anywhere is supported by the fact that startups in emerging venture communities are often more capital efficient, offer a lower cost of doing business, and attract talent looking for a better quality of life.

Revolution

Upfront Ventures is proud to be an early investor and long-term partner to the most exciting founders and startups. Founded in 1996 in Los Angeles with investing professionals based in LA, San Francisco, and Paris, Upfront has backed standout teams across all technology sectors, including Ring (acq. by Amazon), TrueCar (NASDAQ: TRUE), Bird, Maker Studios (acq by Disney), GOAT, Apeel Sciences, thredUP, Invoca and Kyriba (acq by Bridgepoint). We invest about half of our capital in the fast-growing Southern California ecosystem, with the balance across the country as well as investments in Europe and Israel. Upfront Ventures is led by Managing Partners Yves Sisteron, Mark Suster, and Kara Nortman.

Upfront Ventures

Compound is a venture capital firm that invests in bleeding-edge technology built by outliers. They have partnered with elite operators that understand the intricacies of many different industries and various components of businesses, that help them navigate the complex systems in which each startup lives by removing roadblocks and compounding growth. Compound is based in New York City.

Compound

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technology.

Khosla Ventures

Revolution’s Rise of the Rest Seed Fund is an outgrowth of Revolution’s Rise of the Rest platform, a national initiative launched in 2014 to spotlight emerging startup hubs. Revolution’s Rise of the Rest Seed Fund invests in seed- and early-stage companies located outside of New York City, Silicon Valley, and Boston. By partnering with regional ecosystem leaders and co-investors, Rise of the Rest is helping to build and scale the next wave of transformational companies. The Rise of the Rest Seed Funds are backed by a group of iconic entrepreneurs and business leaders committed to the vision that the next great startups will be located outside of the coastal tech hubs.

Revolution’s Rise of the Rest Seed Fund

Bold Capital Partners is an early-stage venture capital firm investing in life sciences, healthcare, and frontier tech companies.

Bold Capital Partners

Bioverge is a venture capital firm specializing in emerging healthcare startups. The firm operates an investment platform that aims to democratize access to startups solving healthcare’s biggest challenges and accelerating their progress.

Bioverge

Public Safety Personnel Retirement System Trust provides offers pension, retirement plans, and various other benefits to participants.

Public Safety Personnel Retirement System

OurCrowd is a venture investing platform that enables institutions and individuals to invest and engage in emerging companies. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global 'crowd' gains access to VC-level investment opportunities.

OurCrowd

Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfolio companies.

Dolby Family Ventures

Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital to date.  The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.

Gaingels

Sixty Degree Capital is a North American VC that invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO). The firm has a global investment mandate, but currently focuses on the US market.

Sixty Degree Capital

What If Ventures invests in stigmatized verticals within the healthcare market. For too long, stigma has artificially suppressed demand for care in indications such as mental health, fertility, and many others.  Societal changes are creating markets where stigma once stood in the way of people getting the care they need. The firm was founded in 2019 by Stephen Hays, after his own personal struggles with mental health and addiction fueled his desire to see more funding for solutions in that space.  Since then, the firm has broadened its aperture and has deployed nearly $80mm into more than 60 disruptive healthcare startups.

What If Ventures

GISEV Family Office is a investment firm.

GISEV Family Office

Deep Insight is the first Israeli venture fund to invest only in Deep Tech at all stages and across all sectors, including semiconductors and any scientific or technological breakthrough in physics or life science.

Deep Insight

Flucas Ventures is a venture capital investor.

Flucas Ventures

Sand Hill Angels is a group of Silicon Valley angel investors passionate about helping entrepreneurs get to the next level. What makes the group unique is the collective experience of its members building and scaling deep technology companies. The group has been around for more than two decades. Sand Hill Angels works openly and collaboratively with venture capital funds, other angel organizations, and the Bay Area ecosystem that fosters the growth of technology startups.  For additional information, visit www.sandhillangels.com or follow @SandHillAngels.com on Twitter.

Sand Hill Angels

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

Bionaut Labs

Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index for efficacy and maintain safety. Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings.

Bionaut Labs develops microrobots for precision drug delivery in the human body. Its flagship technology involves microrobots about the size of a grain of rice, designed to navigate through the bloodstream and tissue to deliver drugs with exceptional accuracy. These microrobots are controlled using magnetism, with Bionaut's scientists and engineers guiding them by manipulating electromagnetic fields.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Bionaut Labs Revolutionizing Brain Disease Treatment with MicroRobots

Bionaut Labs develops microrobots for precision drug delivery in the human body. Its flagship technology involves microrobots about the size of a grain of rice, designed to navigate through the bloodstream and tissue to deliver drugs with exceptional accuracy. These microrobots are controlled using magnetism, with Bionaut's scientists and engineers guiding them by manipulating electromagnetic fields.The company's initial focus was treating neurological conditions like cancer and Parkinson's disease by delivering drugs directly to the brain. Its first clinical trials, scheduled for late 2024, aimed to target Dandy-Walker Syndrome, a condition characterized by fluid accumulation in the brain.&nbsp;With successful animal testing, it has secured significant funding, including support from the Mayo Clinic and Bill Gates' Gates Ventures.&nbsp;Key customers and partnershipsIn December 2021, it partnered with Candel Therapeutics to advance the precision-targeted delivery of oncolytic viral immunotherapies utilizing Bionaut's micro-robotic technology under an integrated electromagnetic control system, facilitating minimally invasive delivery directly to brain tumors.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Bionaut Labs

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless